Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025. Pharmaceutical Executive: What’s causing the increase in M&A in 2025? Ash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback